Literature DB >> 30013296

Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in Adults With Chronic Kidney Disease on Hemodialysis.

Jena Patel, Mary Barna Bridgeman.   

Abstract

Etelcalcetide (Parsabiv) for hyperparathyroidism in adults with chronic kidney disease on hemodialysis.

Entities:  

Year:  2018        PMID： 30013296      PMCID： PMC6027851     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  5 in total

1.  Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.

Authors:  Geoffrey A Block; David A Bushinsky; Sunfa Cheng; John Cunningham; Bastian Dehmel; Tilman B Drueke; Markus Ketteler; Reshma Kewalramani; Kevin J Martin; Sharon M Moe; Uptal D Patel; Justin Silver; Yan Sun; Hao Wang; Glenn M Chertow
Journal:  JAMA       Date:  2017-01-10       Impact factor: 56.272

2.  Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.

Authors:  Geoffrey A Block; David A Bushinsky; John Cunningham; Tilman B Drueke; Markus Ketteler; Reshma Kewalramani; Kevin J Martin; T Christian Mix; Sharon M Moe; Uptal D Patel; Justin Silver; David M Spiegel; Lulu Sterling; Liron Walsh; Glenn M Chertow
Journal:  JAMA       Date:  2017-01-10       Impact factor: 56.272

3.  Medicare Program; End-Stage Renal Disease Prospective Payment System, and Quality Incentive Program. Final Rule.

Authors: 
Journal:  Fed Regist       Date:  2015-11-06

4.  Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.

Authors:  P Chen; P Olsson Gisleskog; J J Perez-Ruixo; J Xiao; J Wilkins; A Narayanan; J P Gibbs; M Melhem
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-09-17

5.  A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism.

Authors:  Keitaro Yokoyama; Masafumi Fukagawa; Takashi Shigematsu; Takashi Akiba; Akifumi Fujii; Akinori Yamauchi; Motoi Odani; Tadao Akizawa
Journal:  Kidney Int Rep       Date:  2017-02-20
  5 in total
  2 in total

Review 1.  Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism.

Authors:  Tadao Akizawa; Kazuaki Ikejiri; Yuichiro Kondo; Yuichi Endo; Masafumi Fukagawa
Journal:  Ther Apher Dial       Date:  2019-10-23       Impact factor: 2.195

2.  First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties.

Authors:  Junichiro James Kazama; Fumihiko Koiwa; Keitaro Yokoyama; Masafumi Fukagawa; Kenji Asano; Daisuke Honda; Tadao Akizawa
Journal:  Clin Pharmacokinet       Date:  2022-06-28       Impact factor: 5.577
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.